A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

October 1, 2026

Study Completion Date

October 2, 2026

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Iptacopan (LNP023)

oral capsules

DRUG

Placebo

oral capsules

Trial Locations (28)

21209

Retina Care Center, Baltimore

27705

Duke Eye Center, Durham

33064

Advanced Research LLC, Deerfield Beach

33484

Retina Center Of South Florida, Delray Beach

33711

Retina Vitreous Associates of Florida, St. Petersburg

38138

Charles Retina Institute, Germantown

46280

Midwest Eye Institute, Indianapolis

75231

Retina Foundation, Dallas

76104

Texas Retina Associates, Fort Worth

77030

Retina Consultants of Houston PA, Houston

77401

Retina Consultants TX Rsrch Ctr, Bellaire

78793

Austin Research Center for Retina, Austin

81303

Southwest Retina Research Center, Durango

92647

Salehi Retina Institute, Huntington Beach

92835

Retina Consultants of Orange County, Fullerton

93103

California Retina Consultants, Santa Barbara

95670

Martel Eye Medical Group, Rancho Cordova

95841

Retinal Consultants Medical Group Inc, Sacramento

97210

Retina Northwest PC, Portland

150001

Novartis Investigative Site, Harbin

200080

Novartis Investigative Site, Shanghai

300020

Novartis Investigative Site, Tianjin

70115 8139

Retina Associates New Orleans, New Orleans

02114

Opthamalic Consultants of Boston, Boston

07003

Envision Ocular LLC, Bloomfield

00612

Emanuelli Research and Development Center LLC, Arecibo

SE5 9RS

Novartis Investigative Site, London

SO16 6YD

Novartis Investigative Site, Southampton

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY